<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03160885</url>
  </required_header>
  <id_info>
    <org_study_id>LP0162-1326</org_study_id>
    <secondary_id>2016-004201-13</secondary_id>
    <nct_id>NCT03160885</nct_id>
  </id_info>
  <brief_title>Tralokinumab Monotherapy for Moderate to Severe Atopic Dermatitis - ECZTRA 2 (ECZema TRAlokinumab Trial no. 2)</brief_title>
  <acronym>ECZTRA 2</acronym>
  <official_title>A Randomised, Double-blind, Placebo-controlled, Phase 3 Trial to Evaluate the Efficacy and Safety of Tralokinumab Monotherapy in Subjects With Moderate to Severe Atopic Dermatitis Who Are Candidates for Systemic Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LEO Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>LEO Pharma</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary objective:&#xD;
&#xD;
      To evaluate the efficacy of tralokinumab compared with placebo in treating moderate to severe&#xD;
      atopic dermatitis (AD).&#xD;
&#xD;
      Secondary objectives:&#xD;
&#xD;
      To evaluate the efficacy of tralokinumab on severity and extent of AD, itch, and health&#xD;
      related quality of life compared with placebo.&#xD;
&#xD;
      Maintenance objective:&#xD;
&#xD;
      To evaluate maintenance of effect with continued tralokinumab dosing up to 52 weeks compared&#xD;
      to placebo for subjects achieving clinical response at Week 16.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects found eligible following the screening period were randomized 3:1 to initial&#xD;
      treatment with tralokinumab 300 mg every 2 weeks (Q2W) or placebo. Randomization was&#xD;
      stratified by region (Asia, Australia, Europe, and North America) and disease severity&#xD;
      (Investigator's Global Assessment [IGA] 3 or 4).&#xD;
&#xD;
      Subjects achieving a clinical response at Week 16 (defined as IGA of 0 or 1 on a 5-point&#xD;
      scale ranging from 0 [clear] to 4 [severe], or at least 75% reduction in Eczema Area and&#xD;
      Severity Index [EASI] score from baseline [EASI75]) continued into maintenance treatment that&#xD;
      continued until Week 52.&#xD;
&#xD;
      Subjects randomized to tralokinumab in the initial treatment period and who achieved a&#xD;
      clinical response at Week 16 (defined by IGA 0 or 1, or EASI75) were re-randomized 2:2:1 to&#xD;
      one of the following Q2W maintenance regimens stratified by region (Asia, Australia, Europe,&#xD;
      and North America) and IGA response at Week 16 (IGA 0/1 or IGA &gt;1):&#xD;
&#xD;
        -  Tralokinumab 300 mg Q2W.&#xD;
&#xD;
        -  Tralokinumab 300 mg Q4W (alternating dose administrations tralokinumab 300 mg and&#xD;
           placebo).&#xD;
&#xD;
        -  Placebo.&#xD;
&#xD;
      Subjects randomized to placebo in the initial treatment period who achieved a clinical&#xD;
      response at Week 16 (defined by IGA 0 or 1, or EASI75) continued to receive placebo Q2W in&#xD;
      the maintenance treatment period.&#xD;
&#xD;
      Subjects not achieving a clinical response at Week 16 as well as those who met the criteria&#xD;
      listed below during maintenance treatment were transferred to open-label tralokinumab 300 mg&#xD;
      Q2W treatment with optional use of topical corticosteroid (TCS) up to Week 52.&#xD;
&#xD;
      Transfer to open-label treatment during maintenance:&#xD;
&#xD;
      Subjects with IGA=0 at Week 16: IGA of at least 2 and not achieved EASI75 over at least a&#xD;
      4-week period (i.e. over 3 consecutive visits).&#xD;
&#xD;
      Subjects with IGA=1 at Week 16: IGA of at least 3 and not achieved EASI75 over at least a&#xD;
      4-week period (i.e. over 3 consecutive visits).&#xD;
&#xD;
      Subjects with IGA &gt;1 at Week 16: not achieved EASI75 over at least a 4-week period (i.e. over&#xD;
      3 consecutive visits).&#xD;
&#xD;
      Subjects transferring to open-label treatment had the option to self-administer tralokinumab&#xD;
      in their home after adequate training (at 3 dosing visits in the open-label period after&#xD;
      additional consent has been obtained) by site staff at the investigator's discretion.&#xD;
&#xD;
      After completion of the maintenance treatment period (or open-label treatment), all subjects,&#xD;
      except for those who entered the open-label long-term extension trial, continued in a 14-week&#xD;
      off-treatment follow-up period for the assessment of safety and anti-drug antibody (ADA).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 12, 2017</start_date>
  <completion_date type="Actual">August 14, 2019</completion_date>
  <primary_completion_date type="Actual">September 4, 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Neither the subject nor any of the investigator or LEO staff who are involved in the treatment or clinical evaluation and monitoring of the subjects will be aware of the treatment received. The packaging and labelling of the investigational medicinal products (IMPs) will contain no evidence of their identity.&#xD;
Since tralokinumab and placebo are visually distinct and not matched for viscosity, IMP will be handled and administered by a qualified, unblinded healthcare professional (HCP) at the site who will not be involved in the management of trial subjects and who will not perform any of the assessments.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Subjects With Investigator's Global Assessment (IGA) Score of 0 (Clear) or 1 (Almost Clear) at Week 16.</measure>
    <time_frame>At Week 16</time_frame>
    <description>The IGA is an instrument used in clinical trials to rate the severity of the subject's global AD and is based on a 5-point scale ranging from 0 (clear) to 4 (severe).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Subjects Achieving at Least 75% Reduction in Eczema Area and Severity Index [EASI].</measure>
    <time_frame>At Week 16</time_frame>
    <description>The EASI is a validated measure used in clinical practice and clinical trials to assess the severity and extent of AD. The EASI is a composite index with scores ranging from 0 to 72, with higher values indicating more severe and/or more extensive condition.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Reduction of Worst Daily Pruritus Numeric Rating Scale (Weekly Average) of at Least 4 From Baseline to Week 16.</measure>
    <time_frame>Week 0 to Week 16</time_frame>
    <description>Subjects will assess their worst itch severity over the past 24 hours using an 11 point NRS ('Worst Daily Pruritus NRS') with 0 indicating 'no itch' and 10 indicating 'worst itch imaginable'.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Scoring Atopic Dermatitis (SCORAD) From Baseline to Week 16.</measure>
    <time_frame>Week 0 to Week 16</time_frame>
    <description>The SCORAD is a validated tool to evaluate the extent and severity of AD lesions, along with subjective symptoms. The maximum total score is 103, with higher values indicating more severe disease.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Dermatology Life Quality Index (DLQI) Score From Baseline to Week 16.</measure>
    <time_frame>Week 0 to Week 16</time_frame>
    <description>The DLQI is a validated questionnaire with content specific to those with dermatology conditions. It consists of 10 items addressing the subject's perception of the impact of their skin disease on different aspects of their quality of life (QoL) over the last week such as dermatology-related symptoms and feelings, daily activities, leisure, work or school, personal relationships, and the treatment. Each item is scored on a 4 point Likert scale (0 = not at all/not relevant; 1 = a little; 2 = a lot; 3 = very much). The total score is the sum of the 10 items (0 to 30); a high score is indicative of a poor QoL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjects With Investigator's Global Assessment (IGA) Score of 0 (Clear) or 1 (Almost Clear) at Week 52 Among Subjects With IGA of 0/1 at Week 16</measure>
    <time_frame>At Week 52</time_frame>
    <description>The IGA is an instrument used in clinical trials to rate the severity of the subject's global AD and is based on a 5-point scale ranging from 0 (clear) to 4 (severe).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjects With at Least 75% Reduction in Eczema Area and Severity Index [EASI] at Week 52 Among Subjects With EASI75 at Week 16</measure>
    <time_frame>At Week 52</time_frame>
    <description>The EASI is a validated measure used in clinical practice and clinical trials to assess the severity and extent of AD. The EASI is a composite index with scores ranging from 0 to 72, with higher values indicating more severe and/or more extensive condition.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and Tolerability: Adverse Event (AE) /Serious Adverse Event (SAE) Frequency</measure>
    <time_frame>Week 0 to Week 16</time_frame>
    <description>Overall summary of AEs and SAEs during the Initial treatment period is presented. For list of AEs and SAEs by MedDRA system organ class (SOC) and preferred term (PT) during the entire trial period (including safety follow-up), see Adverse Events Overview section.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of Anti-drug Antibodies</measure>
    <time_frame>Week 0 to Week 16</time_frame>
    <description>Anti-tralokinumab antibody levels were analysed using a validated bioanalytical method</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjects Achieving at Least 50% Reduction in Eczema Area and Severity Index [EASI] at Week 16</measure>
    <time_frame>At Week 16</time_frame>
    <description>The EASI is a validated measure used in clinical practice and clinical trials to assess the severity and extent of AD. The EASI is a composite index with scores ranging from 0 to 72, with higher values indicating more severe and/or more extensive condition.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjects Achieving at Least 90% Reduction in Eczema Area and Severity Index [EASI] at Week 16.</measure>
    <time_frame>At Week 16</time_frame>
    <description>The EASI is a validated measure used in clinical practice and clinical trials to assess the severity and extent of AD. The EASI is a composite index with scores ranging from 0 to 72, with higher values indicating more severe and/or more extensive condition.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 16 in Eczema Area and Severity Index [EASI] Score</measure>
    <time_frame>At Week 16</time_frame>
    <description>The EASI is a validated measure used in clinical practice and clinical trials to assess the severity and extent of AD. The EASI is a composite index with scores ranging from 0 to 72, with higher values indicating more severe and/or more extensive condition.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjects Achieving at Least 75% Reduction in Scoring Atopic Dermatitis (SCORAD) at Week 16.</measure>
    <time_frame>At Week 16</time_frame>
    <description>The SCORAD is a validated tool to evaluate the extent and severity of AD lesions, along with subjective symptoms. The maximum total score is 103, with higher values indicating more severe disease.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjects Achieving at Least 50% Reduction in Scoring Atopic Dermatitis (SCORAD) at Week 16.</measure>
    <time_frame>At Week 16</time_frame>
    <description>The SCORAD is a validated tool to evaluate the extent and severity of AD lesions, along with subjective symptoms. The maximum total score is 103, with higher values indicating more severe disease.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 16 in Worst Daily Pruritus NRS (Weekly Average).</measure>
    <time_frame>Baseline to Week 16</time_frame>
    <description>Subjects will assess their worst itch severity over the past 24 hours using an 11 point NRS ('Worst Daily Pruritus NRS') with 0 indicating 'no itch' and 10 indicating 'worst itch imaginable'</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction of Worst Daily Pruritus NRS (Weekly Average) ≥3 From Baseline to Week 16.</measure>
    <time_frame>Baseline to Week 16</time_frame>
    <description>Subjects will assess their worst itch severity over the past 24 hours using an 11 point NRS ('Worst Daily Pruritus NRS') with 0 indicating 'no itch' and 10 indicating 'worst itch imaginable'.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction From Baseline to Week 16 of Dermatology Life Quality Index (DLQI) of ≥4 Points Among Subjects With Baseline DLQI ≥4.</measure>
    <time_frame>Baseline to Week 16</time_frame>
    <description>The DLQI is a validated questionnaire with content specific to those with dermatology conditions. It consists of 10 items addressing the subject's perception of the impact of their skin disease on different aspects of their QoL over the last week such as dermatology related symptoms and feelings, daily activities, leisure, work or school, personal relationships, and the treatment. Each item is scored on a 4 point Likert scale (0 = not at all/not relevant; 1 = a little; 2 = a lot; 3 = very much). The total score is the sum of the 10 items (0 to 30); a high score is indicative of a poor QoL.</description>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Actual">794</enrollment>
  <condition>Atopic Dermatitis</condition>
  <arm_group>
    <arm_group_label>Initial treatment period - Tralokinumab Q2W</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Week 0 to Week 16&#xD;
Two subcutaneous (SC) injections of tralokinumab as a loading dose on Day 0, followed by a SC injection of tralokinumab Q2W regimen for 16 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Initial treatment period - Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Week 0 to Week 16 (Initial treatment period):&#xD;
Two subcutaneous (SC) injections of placebo as a loading dose on Day 0 followed by a SC injection of placebo Q2W regimen for 16 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Maintenance treatment period - Tralokinumab Q2W</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Week 16 to Week 52&#xD;
Tralokinumab responders from the initial treatment period re-randomised at Week 16 and administered tralokinumab maintenance subcutaneous injection regimen Q2W for 36 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Maintenance treatment period - Tralokinumab Q4W</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Week 16 to Week 52&#xD;
Tralokinumab responders from the initial treatment period re-randomised at Week 16 and administered tralokinumab maintenance subcutaneous injection regimen Q4W for 36 weeks.&#xD;
Participants in this group receive alternating doses of tralokinumab SC injection and placebo SC injection every 2 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Maintenance treatment period - Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Week 16 to Week 52&#xD;
Tralokinumab responders from initial treatment period randomised at Week 16 and administered placebo subcutaneous maintenance injection for 36 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Maintenance treatment period - Placebo (tralokinumab naive)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Week 16 to Week 52&#xD;
Placebo responders from the initial treatment period re-assigned at Week 16 and administered placebo maintenance subcutaneous injection regimen Q2W for 36 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Open-label treatment - Tralokinumab 300 mg Q2W + optional TCS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Week 16 to Week 52&#xD;
Subjects receiving initial treatment with tralokinumab Q2W or placebo Q2W assigned to open-label treatment at Week 16 and administered tralokinumab subcutaneous (SC) injection + optional TCS* regimen Q2W&#xD;
OR&#xD;
Subjects receiving maintenance treatment with tralokinumab Q2W/Q4W or placebo assigned to open-label treatment after Week 16 and administered tralokinumab SC injection + optional TCS regimen Q2W&#xD;
• TCS = topical corticosteroids</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tralokinumab</intervention_name>
    <description>Tralokinumab is a human recombinant monoclonal antibody of the IgG4 subclass that specifically binds to human IL-13 and blocks interaction with the IL-13 receptors. It is presented as a liquid formulation for subcutaneous (SC) administration</description>
    <arm_group_label>Initial treatment period - Tralokinumab Q2W</arm_group_label>
    <arm_group_label>Maintenance treatment period - Tralokinumab Q2W</arm_group_label>
    <arm_group_label>Maintenance treatment period - Tralokinumab Q4W</arm_group_label>
    <arm_group_label>Open-label treatment - Tralokinumab 300 mg Q2W + optional TCS</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo contains the same excipients, in the same concentration only lacking tralokinumab</description>
    <arm_group_label>Initial treatment period - Placebo</arm_group_label>
    <arm_group_label>Maintenance treatment period - Placebo</arm_group_label>
    <arm_group_label>Maintenance treatment period - Placebo (tralokinumab naive)</arm_group_label>
    <arm_group_label>Maintenance treatment period - Tralokinumab Q4W</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 18 and above.&#xD;
&#xD;
          -  Diagnosis of AD as defined by the Hanifin and Rajka (1980) criteria for AD.&#xD;
&#xD;
          -  Diagnosis of AD for ≥1 year.&#xD;
&#xD;
          -  Subjects who have a recent history of inadequate response to treatment with topical&#xD;
             medications or for whom topical treatments are otherwise medically inadvisable.&#xD;
&#xD;
          -  AD involvement of ≥10% body surface area at screening and baseline.&#xD;
&#xD;
          -  Subjects must have applied a stable dose of emollient twice daily (or more, as needed)&#xD;
             for at least 14 days before randomization&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Active dermatologic conditions that may confound the diagnosis of AD.&#xD;
&#xD;
          -  Use of tanning beds or phototherapy within 6 weeks prior to randomisation.&#xD;
&#xD;
          -  Treatment with systemic immunosuppressive/immunomodulating drugs and/or systemic&#xD;
             corticosteroid within 4 weeks prior to randomisation.&#xD;
&#xD;
          -  Treatment with TCS and/or topical calcineurin inhibitor (TCI) within 2 weeks prior to&#xD;
             randomisation.&#xD;
&#xD;
          -  Active skin infection within 1 week prior to randomisation.&#xD;
&#xD;
          -  Clinically significant infection within 4 weeks prior to randomisation.&#xD;
&#xD;
          -  A helminth parasitic infection within 6 months prior to the date informed consent is&#xD;
             obtained.&#xD;
&#xD;
          -  Tuberculosis requiring treatment within the 12 months prior to screening.&#xD;
&#xD;
          -  Known primary immunodeficiency disorder.&#xD;
&#xD;
          -  Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) level ≥2.0 times&#xD;
             the upper limit of normal (ULN) at screening.&#xD;
&#xD;
          -  Positive hepatitis B surface antigen, hepatitis B surface antibody, hepatitis B core&#xD;
             antibody or hepatitis C virus antibody serology at screening.&#xD;
&#xD;
          -  History of anaphylaxis following any biologic therapy.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eric Simpson, MD, MCR</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Dermatology, Oregon Health and Science University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Burke Pharmaceutical Research</name>
      <address>
        <city>Hot Springs</city>
        <state>Arkansas</state>
        <zip>71913</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>California dermatology</name>
      <address>
        <city>Encinitas</city>
        <state>California</state>
        <zip>92024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advanced SkinCare Surgery &amp; Med Center</name>
      <address>
        <city>Fullerton</city>
        <state>California</state>
        <zip>92835</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>USC Department of Dermatology</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Thiele Dermatology Specialists, Inc</name>
      <address>
        <city>Murrieta</city>
        <state>California</state>
        <zip>92562</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Island Dermatology</name>
      <address>
        <city>Newport Beach</city>
        <state>California</state>
        <zip>92660</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Therapeutics Clinical Research</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>San Luis Dermatology and Laser Clinic</name>
      <address>
        <city>San Luis Obispo</city>
        <state>California</state>
        <zip>93405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southern California Dermatology, Inc.</name>
      <address>
        <city>Santa Ana</city>
        <state>California</state>
        <zip>92701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Olympian Clinical Research</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <zip>33756</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spotlight Research Center, LLC</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33176</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Private Practice - Dr. Tory P. Sullivan</name>
      <address>
        <city>North Miami Beach</city>
        <state>Florida</state>
        <zip>33162</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Marietta Dermatology Clinical Research, Inc.</name>
      <address>
        <city>Marietta</city>
        <state>Georgia</state>
        <zip>30060</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MedaPhase, Inc.</name>
      <address>
        <city>Newnan</city>
        <state>Georgia</state>
        <zip>30263</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>RUSH University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dawes-Fretzin Clinical Research Group, LLC</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46256</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kansas City Dermatology, PA</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beacon Clinical Research</name>
      <address>
        <city>Quincy</city>
        <state>Massachusetts</state>
        <zip>02169</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HFMC New Center One</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Grekin Skin Institute</name>
      <address>
        <city>Warren</city>
        <state>Michigan</state>
        <zip>48088</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Respiratory Medicine Research Institute of Michigan, PLC</name>
      <address>
        <city>Ypsilanti</city>
        <state>Michigan</state>
        <zip>48197</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Studies Group</name>
      <address>
        <city>Henderson</city>
        <state>Nevada</state>
        <zip>89074</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Psoriasis Treatment Center of Central New Jersey</name>
      <address>
        <city>East Windsor</city>
        <state>New Jersey</state>
        <zip>08520</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Corning Center for Clinical Research</name>
      <address>
        <city>Corning</city>
        <state>New York</state>
        <zip>14830</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Icahn School of Medicine at Mount Sinai</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sadick Dermatology</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10075</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wake Forest University Health Sciences</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Cincinnati Health Physicians Office</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45267</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wright State Physicians</name>
      <address>
        <city>Fairborn</city>
        <state>Ohio</state>
        <zip>45324</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aventiv Research Inc.</name>
      <address>
        <city>Westerville</city>
        <state>Ohio</state>
        <zip>43082</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Dermatology and Research Center</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Paddington Testing Company, Inc.</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yardley Dermatology Associates</name>
      <address>
        <city>Yardley</city>
        <state>Pennsylvania</state>
        <zip>19067</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Center of the Carolinas</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29407</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rivergate Dermatology Clinical Research Center</name>
      <address>
        <city>Goodlettsville</city>
        <state>Tennessee</state>
        <zip>37072</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bellaire Dermatology Associates</name>
      <address>
        <city>Bellaire</city>
        <state>Texas</state>
        <zip>77401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Modern Research Associates, PLLC</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Austin Institute for Clinical Research, Inc.</name>
      <address>
        <city>Pflugerville</city>
        <state>Texas</state>
        <zip>78660</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Progressive Clinical Research</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Woden Dermatology Pty Ltd.</name>
      <address>
        <city>Phillip</city>
        <state>Australian Capital Territory</state>
        <zip>2606</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Skin &amp; Cancer Foundation Australia</name>
      <address>
        <city>Darlinghurst</city>
        <state>New South Wales</state>
        <zip>2010</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. George Dermatology and Skin Cancer Center</name>
      <address>
        <city>Kogarah</city>
        <state>New South Wales</state>
        <zip>2217</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Veracity Clinical Research</name>
      <address>
        <city>Woolloongabba</city>
        <state>Queensland</state>
        <zip>4102</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Skin &amp; Cancer Foundation Inc.</name>
      <address>
        <city>Carlton</city>
        <state>Victoria</state>
        <zip>3053</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sinclair Dermatology</name>
      <address>
        <city>East Melbourne</city>
        <state>Victoria</state>
        <zip>3002</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Burswood Dermatology</name>
      <address>
        <city>Victoria Park</city>
        <state>Western Australia</state>
        <zip>6100</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Chih-ho Hong Medical</name>
      <address>
        <city>Surrey</city>
        <state>British Columbia</state>
        <zip>V3R 6A7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Enverus Medical Research</name>
      <address>
        <city>Surrey</city>
        <state>British Columbia</state>
        <zip>V3V 0C6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pacific Derm</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6H 4E1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Winnipeg Clinic</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R3C 0N2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wiseman Dermatology Research</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R3M 3Z4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brunswick Dermatology Centre</name>
      <address>
        <city>Fredericton</city>
        <state>New Brunswick</state>
        <zip>E3B 1G9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nexus Clinical Research</name>
      <address>
        <city>St. John's</city>
        <state>Newfoundland and Labrador</state>
        <zip>A1A 5E8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eastern Canada Cutaneous Research</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B5H 1Z4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kingsway Clinical Research</name>
      <address>
        <city>Etobicoke</city>
        <state>Ontario</state>
        <zip>M8X 1Y9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Guenther Derm Research Centre</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 3H7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lynderm Research Inc.</name>
      <address>
        <city>Markham</city>
        <state>Ontario</state>
        <zip>L3P 1X2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DermEdge Research</name>
      <address>
        <city>Mississauga</city>
        <state>Ontario</state>
        <zip>L5H 1G9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatology &amp; Cosmetic Surgery</name>
      <address>
        <city>North Bay</city>
        <state>Ontario</state>
        <zip>P1B 3Z7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Derm Clinic of Dr. Robern</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K2G 6E2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Skin Centre for Dermatology</name>
      <address>
        <city>Peterborough</city>
        <state>Ontario</state>
        <zip>K9J 5K2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatology &amp; Cosmetic Surgery</name>
      <address>
        <city>Richmond Hill</city>
        <state>Ontario</state>
        <zip>L4B 1A5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>K. Papp</name>
      <address>
        <city>Waterloo</city>
        <state>Ontario</state>
        <zip>N2J 1C4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>XLR8 Medical Research</name>
      <address>
        <city>Windsor</city>
        <state>Ontario</state>
        <zip>N8W 1E6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. David Gratton Dermatologue</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H3H 1V4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CRDQ</name>
      <address>
        <city>Québec</city>
        <state>Quebec</state>
        <zip>G1V 4X7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aarhus University Hospital</name>
      <address>
        <city>Aarhus</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bispebjerg Hospital</name>
      <address>
        <city>Hellerup</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gentofte Hospital</name>
      <address>
        <city>Hellerup</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spedali Civili Brescia</name>
      <address>
        <city>Brescia</city>
        <zip>25123</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico-Vittorio Emanuele</name>
      <address>
        <city>Catania</city>
        <zip>95123</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Opedale San Salvatore</name>
      <address>
        <city>L'Aquila</city>
        <zip>67100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AOU Pisa</name>
      <address>
        <city>Pisa</city>
        <zip>56126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IRCCS San Gallicano</name>
      <address>
        <city>Rom</city>
        <zip>00144</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico &quot;Agostino Gemelli&quot;</name>
      <address>
        <city>Rom</city>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Clinico Humanitas</name>
      <address>
        <city>Rozzano</city>
        <zip>20089</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pusan National University Hospital</name>
      <address>
        <city>Busan</city>
        <zip>49241</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chungnam National Univeristy</name>
      <address>
        <city>Daejeon</city>
        <zip>35015</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chonnam National University Hospital</name>
      <address>
        <city>Gwangju</city>
        <zip>61469</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Soon Chun Hyang University Hospital</name>
      <address>
        <city>Gyeonggi-do</city>
        <zip>14584</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Korea University Ansan Hospital</name>
      <address>
        <city>Gyeonggi-do</city>
        <zip>425-707</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Mary's Hospital</name>
      <address>
        <city>Incheon</city>
        <zip>21431</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inha University Hospital</name>
      <address>
        <city>Incheon</city>
        <zip>22332</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yonsei University Health Syste</name>
      <address>
        <city>Seoul</city>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Konkuk University Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>05030</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chung-Ang University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>06973</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hallym University Kangnam Sacr</name>
      <address>
        <city>Seoul</city>
        <zip>07441</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Medyczne Gdynia</name>
      <address>
        <city>Gdynia</city>
        <zip>81-338</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synexus Polska Gdyni</name>
      <address>
        <city>Gdynia</city>
        <zip>81-384</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synexus Polska Katowicach</name>
      <address>
        <city>Katowice</city>
        <zip>40-040</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Medyczne PRATIA</name>
      <address>
        <city>Kraków</city>
        <zip>30-002</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krakowskie Centrum Medyczne</name>
      <address>
        <city>Kraków</city>
        <zip>31-501</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synexus Polska Poznaniu</name>
      <address>
        <city>Poznań</city>
        <zip>60-702</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinika Dermatologii</name>
      <address>
        <city>Rzeszów</city>
        <zip>35-055</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>&quot;DERMED&quot; Centrum Medyczne Sp.</name>
      <address>
        <city>Łódź</city>
        <zip>90-265</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermoklinika Centrum Medyczne</name>
      <address>
        <city>Łódź</city>
        <zip>90-436</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chelyabinsk Dermat. Dispensary</name>
      <address>
        <city>Chelyabinsk</city>
        <zip>454048</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Federal State Budgetary Institution State Sci. Ctr.</name>
      <address>
        <city>Moscow</city>
        <zip>107076</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>French clinic of skin diseases</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>191123</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Military Medical Academy</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>194044</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ninewells Hospital</name>
      <address>
        <city>Dundee</city>
        <state>Angus</state>
        <zip>DD2 1GZ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Salford Royal Hospital</name>
      <address>
        <city>Salford</city>
        <state>Greater Manchester</state>
        <zip>M6 8HD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Whipps Cross University Hospital</name>
      <address>
        <city>Leytonstone</city>
        <state>London</state>
        <zip>E11 1NR</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Harrogate District Hospital</name>
      <address>
        <city>Harrogate</city>
        <state>North Yorkshire</state>
        <zip>HG2 7SX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Hallamshire Hospital</name>
      <address>
        <city>Sheffield</city>
        <state>South Yorkshire</state>
        <zip>S10 2RX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>East Surrey Hospital</name>
      <address>
        <city>Redhill</city>
        <state>Surrey</state>
        <zip>RH1 5RH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Victoria Infirmary</name>
      <address>
        <city>Newcastle upon Tyne</city>
        <state>Tyne And Wear</state>
        <zip>NE1 4LP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Russells Hall Hospital</name>
      <address>
        <city>Dudley</city>
        <state>West Midlands</state>
        <zip>DY1 2HQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Walsall Healthcare NHS Trust</name>
      <address>
        <city>Walsall</city>
        <state>West Midlands</state>
        <zip>WS2 9PS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chapel Allerton Hospital</name>
      <address>
        <city>Leeds</city>
        <state>West Yorkshire</state>
        <zip>LS7 4SA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West Suffolk Hospital</name>
      <address>
        <city>Bury St Edmunds</city>
        <zip>IP33 2QZ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Whittington Hospital NHS</name>
      <address>
        <city>London</city>
        <zip>N19 5NF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Guy's Hospital</name>
      <address>
        <city>London</city>
        <zip>SE1 9RT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>Denmark</country>
    <country>Italy</country>
    <country>Korea, Republic of</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>May 18, 2017</study_first_submitted>
  <study_first_submitted_qc>May 18, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 19, 2017</study_first_posted>
  <results_first_submitted>August 7, 2020</results_first_submitted>
  <results_first_submitted_qc>August 7, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">August 24, 2020</results_first_posted>
  <disposition_first_submitted>September 2, 2019</disposition_first_submitted>
  <disposition_first_submitted_qc>September 2, 2019</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">September 11, 2019</disposition_first_posted>
  <last_update_submitted>August 7, 2020</last_update_submitted>
  <last_update_submitted_qc>August 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatitis, Atopic</mesh_term>
    <mesh_term>Dermatitis</mesh_term>
    <mesh_term>Eczema</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>De-identified Individual Participant Data can be made available to researchers in a closed environment for a specified period of time.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Data are available to request after results of the trial are available on leopharmatrials.com</ipd_time_frame>
    <ipd_access_criteria>Data-sharing is subject to approved scientifically sound research proposal and signed data-sharing agreement.</ipd_access_criteria>
    <ipd_url>http://leopharmatrials.com/for-professionals</ipd_url>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 14, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/85/NCT03160885/SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>August 14, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/85/NCT03160885/Prot_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>The screening period was 2 and 6 weeks and included 1 or 2 visits. The exact duration depended on the wash-out period defined by the exclusion criteria. If no wash-out or only a 2-week wash-out was required, screening Visits 1 and 2 were combined. Eligibility was assessed at the (first) screening visit and on Day 0 prior to randomization.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Initial Treatment Period - Tralokinumab 300 mg Q2W</title>
          <description>Week 0 to Week 16:&#xD;
Tralokinumab 300 mg Q2W&#xD;
Tralokinumab: Tralokinumab is a human recombinant monoclonal antibody of the IgG4 subclass that specifically binds to human IL-13 and blocks interaction with the IL-13 receptors. It is presented as a liquid formulation for SC administration&#xD;
At Day 0, each subject received 4 SC injections (each 1.0 mL) of 150 mg tralokinumab to receive a total loading dose of 600 mg tralokinumab (4.0 mL). At subsequent visits (Q2W) each subject received 2 SC injections (each 1.0 mL) of 150 mg tralokinumab to receive a total dose of 300 mg tralokinumab</description>
        </group>
        <group group_id="P2">
          <title>Initial Treatment Period - Placebo Q2W</title>
          <description>Week 0 to Week 16:&#xD;
Placebo Q2W&#xD;
Placebo: Placebo contains the same excipients, in the same concentration, only lacking tralokinumab&#xD;
At Day 0, each subject received 4 SC injections (each 1.0 mL) of placebo to receive a total loading dose (4.0 mL). At subsequent visits (Q2W) each subject received 2 SC injections (each 1.0 mL) of placebo</description>
        </group>
        <group group_id="P3">
          <title>Maintenance Treatment Period - Tralokinumab 300 mg Q2W</title>
          <description>Week 16 to Week 52:&#xD;
Subjects achieving a clinical response at Week 16 and initially randomized to tralokinumab re-randomized to tralokinumab 300 mg Q2W maintenance dosing regimen&#xD;
At each visit, subject received 2 SC injections (each 1.0 mL) of 150 mg tralokinumab Q2W to receive a total dose of 300 mg tralokinumab.</description>
        </group>
        <group group_id="P4">
          <title>Maintenance Treatment Period - Tralokinumab 300 mg Q4W</title>
          <description>Week 16 to Week 52:&#xD;
Subjects achieving a clinical response at Week 16 and initially randomized to tralokinumab re-randomized to tralokinumab 300 mg Q4W maintenance dosing regimen&#xD;
At each visit, subject received alternating dose administrations: 2 SC injections (each 1.0 mL) of 150 mg tralokinumab to receive a total dose of 300 mg tralokinumab and 2 SC injections (each 1.0 mL) of placebo.</description>
        </group>
        <group group_id="P5">
          <title>Maintenance Treatment Period - Placebo Q2W</title>
          <description>Week 16 to Week 52:&#xD;
Subjects achieving a clinical response at Week 16 and initially randomized to tralokinumab re-randomized to placebo Q2W dosing regimen&#xD;
At each visit, subject received 2 SC injections (each 1.0 mL) of placebo Q2W to receive a total dose of placebo.</description>
        </group>
        <group group_id="P6">
          <title>Maintenance Treatment Period -Placebo Q2W - Tralokinumab Naive</title>
          <description>Week 16 to Week 52:&#xD;
Subjects achieving a clinical response at Week 16 and initially randomized to placebo re-assigned to placebo Q2W&#xD;
At each visit, subject received 2 SC injections (each 1.0 mL) of placebo Q2W to receive a total dose of placebo.</description>
        </group>
        <group group_id="P7">
          <title>Open-label Treatment -Tralokinumab 300 mg Q2W + Optional TCS</title>
          <description>Week 16 to Week 52:&#xD;
Subjects receiving initial treatment with tralokinumab/placebo Q2W who did not achieve protocol-defined clinical response assigned to open-label treatment at Week 16 with tralokinumab 300 mg Q2W regimen + optional topical corticosteroids (TCS) OR Subjects receiving maintenance treatment with tralokinumab 300 mg Q2W/Q4W or placebo Q2W assigned to open-label treatment after Week 16 with tralokinumab 300 mg Q2W regimen + optional TCS if&#xD;
IGA of at least 2 and not achieving EASI75 over at least a 4-week period (over 3 consecutive visits) for subjects with IGA=0 at Week 16 OR&#xD;
IGA of at least 3 and not achieving EASI75 over at least a 4-week period (i.e. over 3 consecutive visits) for subjects with IGA=1 at Week 16 OR&#xD;
Not achieving EASI75 over at least a 4-week period (over 3 consecutive visits) for subjects with IGA&gt;1 at Week 16&#xD;
At each visit, subject received 2 SC injections (each 1.0 mL) of 150 mg tralokinumab Q2W to receive a total dose of 300 mg</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Initial Treatment Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="593"/>
                <participants group_id="P2" count="201"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="558"/>
                <participants group_id="P2" count="179"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="35"/>
                <participants group_id="P2" count="22"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Not dosed</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Discontinued IMP before Week 16</title>
              <participants_list>
                <participants group_id="P1" count="33"/>
                <participants group_id="P2" count="22"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Open-label Treatment</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="560"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="423"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="137"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Not dosed</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Discontinued IMP</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="131"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Completed Week 50</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Maintenance Treatment Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="91"/>
                <participants group_id="P4" count="90"/>
                <participants group_id="P5" count="46"/>
                <participants group_id="P6" count="31"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="52"/>
                <participants group_id="P4" count="50"/>
                <participants group_id="P5" count="15"/>
                <participants group_id="P6" count="16"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="39"/>
                <participants group_id="P4" count="40"/>
                <participants group_id="P5" count="31"/>
                <participants group_id="P6" count="15"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Not dosed - transfer to open-label</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Discontinued IMP</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="13"/>
                <participants group_id="P5" count="5"/>
                <participants group_id="P6" count="7"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Transfer to open-label treatment</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="29"/>
                <participants group_id="P4" count="26"/>
                <participants group_id="P5" count="26"/>
                <participants group_id="P6" count="8"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Completed Week 50</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Initial Treatment Period - Tralokinumab 300 mg Q2W</title>
          <description>Week 0 to Week 16:&#xD;
Tralokinumab 300 mg Q2W&#xD;
At Day 0, each subject received 4 SC injections (each 1.0 mL) of 150 mg tralokinumab to receive a total loading dose of 600 mg tralokinumab (4.0 mL). At subsequent visits (Q2W) each subject received 2 SC injections (each 1.0 mL) of 150 mg tralokinumab to receive a total dose of 300 mg tralokinumab</description>
        </group>
        <group group_id="B2">
          <title>Initial Treatment Period - Placebo Q2W</title>
          <description>Week 0 to Week 16:&#xD;
Placebo Q2W&#xD;
At Day 0, each subject received 4 SC injections (each 1.0 mL) of placebo to receive a total loading dose (4.0 mL). At subsequent visits (Q2W) each subject received 2 SC injections (each 1.0 mL) of placebo</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="593"/>
            <count group_id="B2" value="201"/>
            <count group_id="B3" value="794"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="593"/>
                    <count group_id="B2" value="201"/>
                    <count group_id="B3" value="794"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37.2" spread="14.7"/>
                    <measurement group_id="B2" value="35.1" spread="14.0"/>
                    <measurement group_id="B3" value="36.7" spread="14.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>18-64 years</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="593"/>
                    <count group_id="B2" value="201"/>
                    <count group_id="B3" value="794"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="563"/>
                    <measurement group_id="B2" value="194"/>
                    <measurement group_id="B3" value="757"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>65-84 years</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="593"/>
                    <count group_id="B2" value="201"/>
                    <count group_id="B3" value="794"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=85 years</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="593"/>
                    <count group_id="B2" value="201"/>
                    <count group_id="B3" value="794"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="593"/>
                    <count group_id="B2" value="201"/>
                    <count group_id="B3" value="794"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="234"/>
                    <measurement group_id="B2" value="87"/>
                    <measurement group_id="B3" value="321"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="359"/>
                    <measurement group_id="B2" value="114"/>
                    <measurement group_id="B3" value="473"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>White</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="593"/>
                    <count group_id="B2" value="201"/>
                    <count group_id="B3" value="794"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="374"/>
                    <measurement group_id="B2" value="123"/>
                    <measurement group_id="B3" value="497"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or african american</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="593"/>
                    <count group_id="B2" value="201"/>
                    <count group_id="B3" value="794"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="593"/>
                    <count group_id="B2" value="201"/>
                    <count group_id="B3" value="794"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="154"/>
                    <measurement group_id="B2" value="52"/>
                    <measurement group_id="B3" value="206"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>American indian or alaska native</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="593"/>
                    <count group_id="B2" value="201"/>
                    <count group_id="B3" value="794"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native hawaiian or other pacific islander</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="593"/>
                    <count group_id="B2" value="201"/>
                    <count group_id="B3" value="794"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="593"/>
                    <count group_id="B2" value="201"/>
                    <count group_id="B3" value="794"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Canada</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="593"/>
                    <count group_id="B2" value="201"/>
                    <count group_id="B3" value="794"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="146"/>
                    <measurement group_id="B2" value="44"/>
                    <measurement group_id="B3" value="190"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>South Korea</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="593"/>
                    <count group_id="B2" value="201"/>
                    <count group_id="B3" value="794"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="593"/>
                    <count group_id="B2" value="201"/>
                    <count group_id="B3" value="794"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="124"/>
                    <measurement group_id="B2" value="47"/>
                    <measurement group_id="B3" value="171"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Denmark</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="593"/>
                    <count group_id="B2" value="201"/>
                    <count group_id="B3" value="794"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Poland</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="593"/>
                    <count group_id="B2" value="201"/>
                    <count group_id="B3" value="794"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Italy</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="593"/>
                    <count group_id="B2" value="201"/>
                    <count group_id="B3" value="794"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United Kingdom</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="593"/>
                    <count group_id="B2" value="201"/>
                    <count group_id="B3" value="794"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Australia</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="593"/>
                    <count group_id="B2" value="201"/>
                    <count group_id="B3" value="794"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="90"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="121"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Russia</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="593"/>
                    <count group_id="B2" value="201"/>
                    <count group_id="B3" value="794"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Investigator's Global Assessment</title>
          <description>The Investigator's Global Assessment (IGA) is an instrument used in clinical trials to rate the severity of the subject's global atopic dermatitis and is based on a 5-point scale ranging from 0 (clear) to 4 (severe)</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="593"/>
                    <count group_id="B2" value="201"/>
                    <count group_id="B3" value="794"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Clear</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Almost clear</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Mild</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Moderate</title>
                  <measurement_list>
                    <measurement group_id="B1" value="305"/>
                    <measurement group_id="B2" value="100"/>
                    <measurement group_id="B3" value="405"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Severe</title>
                  <measurement_list>
                    <measurement group_id="B1" value="286"/>
                    <measurement group_id="B2" value="101"/>
                    <measurement group_id="B3" value="387"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Missing</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Eczema Area and Severity Index</title>
          <description>The Eczema Area and Severity Index (EASI) is a validated measure used in clinical practice and clinical trials to assess the severity and extent of atopic dermatitis. The EASI is a composite index with scores ranging from 0 to 72, with higher values indicating more severe and/or more extensive condition.</description>
          <population>Number of subjects analysed = subjects with available data for the baseline parameter.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="591"/>
                    <count group_id="B2" value="201"/>
                    <count group_id="B3" value="792"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32.1" spread="14.3"/>
                    <measurement group_id="B2" value="32.6" spread="13.9"/>
                    <measurement group_id="B3" value="32.2" spread="14.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Scoring Atopic Dermatitis</title>
          <description>The Scoring Atopic Dermatitis (SCORAD) is a validated tool to evaluate the extent and severity of AD lesions, along with subjective symptoms. The maximum total score is 103, with higher values indicating more severe disease.</description>
          <population>Number of subjects analysed = subjects with available data for the baseline parameter.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="591"/>
                    <count group_id="B2" value="201"/>
                    <count group_id="B3" value="792"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="70.0" spread="13.4"/>
                    <measurement group_id="B2" value="70.5" spread="12.2"/>
                    <measurement group_id="B3" value="70.1" spread="13.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Dermatology Life Quality Index</title>
          <description>The Dermatology Life Quality Index (DLQI) consists of 10 items addressing the subject's perception of the impact of their skin disease on different aspects of their health-related quality of life over the last week such as dermatology-related symptoms and feelings, daily activities, leisure, work or school, personal relationships, and the treatment (1). Each item is scored on a 4-point Likert scale (0='not at all/not relevant'; 1='a little'; 2='a lot'; 3='very much'). The total score is the sum of the 10 items (0 to 30); a high score is indicative of a poor health-related quality of life.</description>
          <population>Number of subjects analysed = subjects with available data for the baseline parameter.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="587"/>
                    <count group_id="B2" value="200"/>
                    <count group_id="B3" value="787"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17.7" spread="7.1"/>
                    <measurement group_id="B2" value="17.8" spread="7.3"/>
                    <measurement group_id="B3" value="17.7" spread="7.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Worst Daily Pruritus Numeric rating scale (weekly average)</title>
          <description>Subjects assess their worst itch severity over the past 24 hours using an 11-point Numeric rating scale (NRS; 'Worst Daily Pruritus NRS') with 0 indicating 'no itch' and 10 indicating 'worst itch imaginable'.</description>
          <population>Number of subjects analysed = subjects with available data for the baseline parameter.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="584"/>
                    <count group_id="B2" value="200"/>
                    <count group_id="B3" value="784"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7.9" spread="1.5"/>
                    <measurement group_id="B2" value="8.0" spread="1.4"/>
                    <measurement group_id="B3" value="7.9" spread="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body surface area affected by AD</title>
          <units>percent</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="593"/>
                    <count group_id="B2" value="201"/>
                    <count group_id="B3" value="794"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52.6" spread="25.6"/>
                    <measurement group_id="B2" value="53.0" spread="25.0"/>
                    <measurement group_id="B3" value="52.7" spread="25.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age of onset of atopic dermatitis (AD)</title>
          <population>Number of subjects analysed = subjects with available data for the baseline parameter.</population>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="592"/>
                    <count group_id="B2" value="201"/>
                    <count group_id="B3" value="793"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.0" lower_limit="1.0" upper_limit="12.0"/>
                    <measurement group_id="B2" value="2.0" lower_limit="1.0" upper_limit="9.0"/>
                    <measurement group_id="B3" value="2.0" lower_limit="1.0" upper_limit="12.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Duration of atopic dermatitis (AD)</title>
          <population>Number of subjects analysed = subjects with available data for the baseline parameter.</population>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="592"/>
                    <count group_id="B2" value="201"/>
                    <count group_id="B3" value="793"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28.3" spread="15.9"/>
                    <measurement group_id="B2" value="27.5" spread="14.7"/>
                    <measurement group_id="B3" value="28.1" spread="15.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Subjects With Investigator's Global Assessment (IGA) Score of 0 (Clear) or 1 (Almost Clear) at Week 16.</title>
        <description>The IGA is an instrument used in clinical trials to rate the severity of the subject's global AD and is based on a 5-point scale ranging from 0 (clear) to 4 (severe).</description>
        <time_frame>At Week 16</time_frame>
        <population>The full analysis set (FAS: all subjects randomised to initial treatment who were exposed to IMP) was used for the primary analysis; 794 subjects were randomised to initial treatment and 792 received IMP, thus the FAS comprised 792 subjects.</population>
        <group_list>
          <group group_id="O1">
            <title>Tralokinumab 300 mg Q2W</title>
            <description>Week 0 to Week 16:&#xD;
Tralokinumab 300 mg Q2W&#xD;
At Day 0, each subject received 4 SC injections (each 1.0 mL) of 150 mg tralokinumab to receive a total loading dose of 600 mg tralokinumab (4.0 mL). At subsequent visits (Q2W) each subject received 2 SC injections (each 1.0 mL) of 150 mg tralokinumab to receive a total dose of 300 mg tralokinumab</description>
          </group>
          <group group_id="O2">
            <title>Placebo Q2W</title>
            <description>Week 0 to Week 16:&#xD;
Placebo Q2W&#xD;
At Day 0, each subject received 4 SC injections (each 1.0 mL) of placebo to receive a total loading dose (4.0 mL). At subsequent visits (Q2W) each subject received 2 SC injections (each 1.0 mL) of placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Subjects With Investigator's Global Assessment (IGA) Score of 0 (Clear) or 1 (Almost Clear) at Week 16.</title>
          <description>The IGA is an instrument used in clinical trials to rate the severity of the subject's global AD and is based on a 5-point scale ranging from 0 (clear) to 4 (severe).</description>
          <population>The full analysis set (FAS: all subjects randomised to initial treatment who were exposed to IMP) was used for the primary analysis; 794 subjects were randomised to initial treatment and 792 received IMP, thus the FAS comprised 792 subjects.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="591"/>
                <count group_id="O2" value="201"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="131"/>
                    <measurement group_id="O2" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analysis was performed using Cochran-Mantel-Haenszel test stratified by region and baseline disease severity.The null hypothesis of no difference in response rates between tralokinumab and placebo were tested against the 2-sided alternative that there is a difference.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Primary endpoints tested sequentially at a 5% significance level.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Based on the primary analysis of the primary estimand 'composite'. Subjects with missing data or subjects who received rescue medication prior to Week 16 were considered non-responders.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Primary endpoints tested sequentially at a 5% significance level.</method_desc>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>11.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>5.8</ci_lower_limit>
            <ci_upper_limit>16.4</ci_upper_limit>
            <estimate_desc>Mantel-Haenszel risk difference, stratified by region and baseline disease severity.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Subjects Achieving at Least 75% Reduction in Eczema Area and Severity Index [EASI].</title>
        <description>The EASI is a validated measure used in clinical practice and clinical trials to assess the severity and extent of AD. The EASI is a composite index with scores ranging from 0 to 72, with higher values indicating more severe and/or more extensive condition.</description>
        <time_frame>At Week 16</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Tralokinumab 300 mg Q2W</title>
            <description>Week 0 to Week 16:&#xD;
Tralokinumab 300 mg Q2W&#xD;
At Day 0, each subject received 4 SC injections (each 1.0 mL) of 150 mg tralokinumab to receive a total loading dose of 600 mg tralokinumab (4.0 mL). At subsequent visits (Q2W) each subject received 2 SC injections (each 1.0 mL) of 150 mg tralokinumab to receive a total dose of 300 mg tralokinumab</description>
          </group>
          <group group_id="O2">
            <title>Placebo Q2W</title>
            <description>Week 0 to Week 16:&#xD;
Placebo Q2W&#xD;
At Day 0, each subject received 4 SC injections (each 1.0 mL) of placebo to receive a total loading dose (4.0 mL). At subsequent visits (Q2W) each subject received 2 SC injections (each 1.0 mL) of placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Subjects Achieving at Least 75% Reduction in Eczema Area and Severity Index [EASI].</title>
          <description>The EASI is a validated measure used in clinical practice and clinical trials to assess the severity and extent of AD. The EASI is a composite index with scores ranging from 0 to 72, with higher values indicating more severe and/or more extensive condition.</description>
          <population>Full analysis set</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="591"/>
                <count group_id="O2" value="201"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="196"/>
                    <measurement group_id="O2" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analysis was performed using Cochran-Mantel-Haenszel test stratified by region and baseline disease severity.The null hypothesis of no difference in response rates between tralokinumab and placebo were tested against the 2-sided alternative that there is a difference.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Primary endpoints tested sequentially at a 5% significance level.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Based on the primary analysis of the primary estimand 'composite'. Subjects with missing data or subjects who received rescue medication prior to Week 16 were considered non-responders.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Primary endpoints tested sequentially at a 5% significance level.</method_desc>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>21.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>15.8</ci_lower_limit>
            <ci_upper_limit>27.3</ci_upper_limit>
            <estimate_desc>Mantel-Haenszel risk difference, stratified by region and baseline disease severity.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Reduction of Worst Daily Pruritus Numeric Rating Scale (Weekly Average) of at Least 4 From Baseline to Week 16.</title>
        <description>Subjects will assess their worst itch severity over the past 24 hours using an 11 point NRS ('Worst Daily Pruritus NRS') with 0 indicating 'no itch' and 10 indicating 'worst itch imaginable'.</description>
        <time_frame>Week 0 to Week 16</time_frame>
        <population>Full analysis set (FAS). Number of subjects analysed = subjects with baseline pruritus NRS weekly average ≥4.</population>
        <group_list>
          <group group_id="O1">
            <title>Tralokinumab 300 mg Q2W</title>
            <description>Week 0 to Week 16:&#xD;
Tralokinumab 300 mg Q2W&#xD;
At Day 0, each subject received 4 SC injections (each 1.0 mL) of 150 mg tralokinumab to receive a total loading dose of 600 mg tralokinumab (4.0 mL). At subsequent visits (Q2W) each subject received 2 SC injections (each 1.0 mL) of 150 mg tralokinumab to receive a total dose of 300 mg tralokinumab</description>
          </group>
          <group group_id="O2">
            <title>Placebo Q2W</title>
            <description>Week 0 to Week 16:&#xD;
Placebo Q2W&#xD;
At Day 0, each subject received 4 SC injections (each 1.0 mL) of placebo to receive a total loading dose (4.0 mL). At subsequent visits (Q2W) each subject received 2 SC injections (each 1.0 mL) of placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Reduction of Worst Daily Pruritus Numeric Rating Scale (Weekly Average) of at Least 4 From Baseline to Week 16.</title>
          <description>Subjects will assess their worst itch severity over the past 24 hours using an 11 point NRS ('Worst Daily Pruritus NRS') with 0 indicating 'no itch' and 10 indicating 'worst itch imaginable'.</description>
          <population>Full analysis set (FAS). Number of subjects analysed = subjects with baseline pruritus NRS weekly average ≥4.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="575"/>
                <count group_id="O2" value="200"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="144"/>
                    <measurement group_id="O2" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Reduction of Worst Daily Pruritus NRS weekly average ≥4 at Week 16 was tested after the sequential testing of IGA 0/1 and EASI75 if these tests showed statistical significance</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Based on the primary analysis of the primary estimand 'Composite', subjects who received rescue medication prior to Week 16 or have missing data at Week 16 were considered as non-responders'.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Tested sequentially at a 5% significance level.</method_desc>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>15.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>10.3</ci_lower_limit>
            <ci_upper_limit>20.9</ci_upper_limit>
            <estimate_desc>Mantel-Haenszel risk difference, stratified by region and baseline disease severity.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Scoring Atopic Dermatitis (SCORAD) From Baseline to Week 16.</title>
        <description>The SCORAD is a validated tool to evaluate the extent and severity of AD lesions, along with subjective symptoms. The maximum total score is 103, with higher values indicating more severe disease.</description>
        <time_frame>Week 0 to Week 16</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Tralokinumab 300 mg Q2W</title>
            <description>Week 0 to Week 16:&#xD;
Tralokinumab 300 mg Q2W&#xD;
At Day 0, each subject received 4 SC injections (each 1.0 mL) of 150 mg tralokinumab to receive a total loading dose of 600 mg tralokinumab (4.0 mL). At subsequent visits (Q2W) each subject received 2 SC injections (each 1.0 mL) of 150 mg tralokinumab to receive a total dose of 300 mg tralokinumab</description>
          </group>
          <group group_id="O2">
            <title>Placebo Q2W</title>
            <description>Week 0 to Week 16:&#xD;
Placebo Q2W&#xD;
At Day 0, each subject received 4 SC injections (each 1.0 mL) of placebo to receive a total loading dose (4.0 mL). At subsequent visits (Q2W) each subject received 2 SC injections (each 1.0 mL) of placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Scoring Atopic Dermatitis (SCORAD) From Baseline to Week 16.</title>
          <description>The SCORAD is a validated tool to evaluate the extent and severity of AD lesions, along with subjective symptoms. The maximum total score is 103, with higher values indicating more severe disease.</description>
          <population>Full analysis set</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="591"/>
                <count group_id="O2" value="201"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-28.1" spread="0.92"/>
                    <measurement group_id="O2" value="-14.0" spread="1.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Data collected after permanent discontinuation of IMP or initiation of rescue medication not included.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Multiplicity adjustment using the Holm method.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Based on the primary analysis of the primary estimand 'hypothetical'. Repeated measurements model on post-baseline data. In case of no post-baseline assessments before initiation of rescue medication, the Week 2 change was imputed as 0.</p_value_desc>
            <method>Repeated measurements model</method>
            <param_type>Difference of least square means</param_type>
            <param_value>-14.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-18.0</ci_lower_limit>
            <ci_upper_limit>-10.1</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Dermatology Life Quality Index (DLQI) Score From Baseline to Week 16.</title>
        <description>The DLQI is a validated questionnaire with content specific to those with dermatology conditions. It consists of 10 items addressing the subject's perception of the impact of their skin disease on different aspects of their quality of life (QoL) over the last week such as dermatology-related symptoms and feelings, daily activities, leisure, work or school, personal relationships, and the treatment. Each item is scored on a 4 point Likert scale (0 = not at all/not relevant; 1 = a little; 2 = a lot; 3 = very much). The total score is the sum of the 10 items (0 to 30); a high score is indicative of a poor QoL.</description>
        <time_frame>Week 0 to Week 16</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Tralokinumab 300 mg Q2W</title>
            <description>Week 0 to Week 16:&#xD;
Tralokinumab 300 mg Q2W&#xD;
At Day 0, each subject received 4 SC injections (each 1.0 mL) of 150 mg tralokinumab to receive a total loading dose of 600 mg tralokinumab (4.0 mL). At subsequent visits (Q2W) each subject received 2 SC injections (each 1.0 mL) of 150 mg tralokinumab to receive a total dose of 300 mg tralokinumab</description>
          </group>
          <group group_id="O2">
            <title>Placebo Q2W</title>
            <description>Week 0 to Week 16:&#xD;
Placebo Q2W&#xD;
At Day 0, each subject received 4 SC injections (each 1.0 mL) of placebo to receive a total loading dose (4.0 mL). At subsequent visits (Q2W) each subject received 2 SC injections (each 1.0 mL) of placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Dermatology Life Quality Index (DLQI) Score From Baseline to Week 16.</title>
          <description>The DLQI is a validated questionnaire with content specific to those with dermatology conditions. It consists of 10 items addressing the subject's perception of the impact of their skin disease on different aspects of their quality of life (QoL) over the last week such as dermatology-related symptoms and feelings, daily activities, leisure, work or school, personal relationships, and the treatment. Each item is scored on a 4 point Likert scale (0 = not at all/not relevant; 1 = a little; 2 = a lot; 3 = very much). The total score is the sum of the 10 items (0 to 30); a high score is indicative of a poor QoL.</description>
          <population>Full analysis set</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="591"/>
                <count group_id="O2" value="201"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.8" spread="0.30"/>
                    <measurement group_id="O2" value="-4.9" spread="0.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Data collected after permanent discontinuation of IMP or initiation of rescue medication not included.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Multiplicity adjustment using Holm method.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Based on the primary analysis of the primary estimand 'hypothetical'. Repeated measurements model on post-baseline data. In case of no post-baseline assessments before initiation of rescue medication, the Week 2 change was imputed as 0.</p_value_desc>
            <method>Repeated measurements model</method>
            <param_type>Difference of least square means</param_type>
            <param_value>-3.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.2</ci_lower_limit>
            <ci_upper_limit>-2.6</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Subjects With Investigator's Global Assessment (IGA) Score of 0 (Clear) or 1 (Almost Clear) at Week 52 Among Subjects With IGA of 0/1 at Week 16</title>
        <description>The IGA is an instrument used in clinical trials to rate the severity of the subject's global AD and is based on a 5-point scale ranging from 0 (clear) to 4 (severe).</description>
        <time_frame>At Week 52</time_frame>
        <population>Maintenance analysis set - Subjects who achieved IGA 0/1 at Week 16 after initial treatment with tralokinumab without use of rescue medication</population>
        <group_list>
          <group group_id="O1">
            <title>Tralokinumab 300 mg Q2W</title>
            <description>Week 16 to Week 52:&#xD;
Subjects achieving a clinical response at Week 16 and initially randomized to tralokinumab re-randomized to tralokinumab 300 mg Q2W maintenance dosing regimen&#xD;
At each visit, subject received 2 SC injections (each 1.0 mL) of 150 mg tralokinumab Q2W to receive a total dose of 300 mg tralokinumab.</description>
          </group>
          <group group_id="O2">
            <title>Tralokinumab 300 mg Q4W</title>
            <description>Week 16 to Week 52:&#xD;
Subjects achieving a clinical response at Week 16 and initially randomized to tralokinumab re-randomized to tralokinumab 300 mg Q4W maintenance dosing regimen&#xD;
At each visit, subject received alternating dose administrations: 2 SC injections (each 1.0 mL) of 150 mg tralokinumab to receive a total dose of 300 mg tralokinumab and 2 SC injections (each 1.0 mL) of placebo.</description>
          </group>
          <group group_id="O3">
            <title>Placebo Q2W</title>
            <description>Week 16 to Week 52:&#xD;
Subjects achieving a clinical response at Week 16 and initially randomized to tralokinumab re-randomized to placebo Q2W dosing regimen&#xD;
At each visit, subject received 2 SC injections (each 1.0 mL) of placebo Q2W to receive a total dose of placebo.</description>
          </group>
        </group_list>
        <measure>
          <title>Subjects With Investigator's Global Assessment (IGA) Score of 0 (Clear) or 1 (Almost Clear) at Week 52 Among Subjects With IGA of 0/1 at Week 16</title>
          <description>The IGA is an instrument used in clinical trials to rate the severity of the subject's global AD and is based on a 5-point scale ranging from 0 (clear) to 4 (severe).</description>
          <population>Maintenance analysis set - Subjects who achieved IGA 0/1 at Week 16 after initial treatment with tralokinumab without use of rescue medication</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="49"/>
                <count group_id="O3" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32"/>
                    <measurement group_id="O2" value="22"/>
                    <measurement group_id="O3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Testing according to the hierarchical testing procedure in the order:&#xD;
IGA 0/1 at Week 52 between Q2W vs Placebo, EASI75 at Week 52 between Q2W vs Placebo, IGA 0/1 at Week 52 between Q4W vs Placebo, and EASI75 at Week 52 between Q4W vs Placebo</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.004</p_value>
            <p_value_desc>Based on the primary analysis of the 'composite' estimand. Subjects who received rescue medication or were transferred to open-label treatment were considered non-responders.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>34.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>13.4</ci_lower_limit>
            <ci_upper_limit>54.9</ci_upper_limit>
            <estimate_desc>Mantel-Haenszel risk difference compared to placebo, stratified by region.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Testing according to the hierarchical testing procedure in the order:&#xD;
IGA 0/1 at Week 52 between Q2W vs Placebo, EASI75 at Week 52 between Q2W vs Placebo, IGA 0/1 at Week 52 between Q4W vs Placebo, and EASI75 at Week 52 between Q4W vs Placebo</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.084</p_value>
            <p_value_desc>Based on the primary analysis of the 'composite' estimand. Subjects who received rescue medication or were transferred to open-label treatment were considered non-responders.&#xD;
P value was considered non-significant</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>This test was not statistically significant and hence next maintenance endpoint in the sequential testing procedure was not evaluated</method_desc>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>19.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.2</ci_lower_limit>
            <ci_upper_limit>40.9</ci_upper_limit>
            <estimate_desc>Mantel-Haenszel risk difference compared to placebo, stratified by region.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Subjects With at Least 75% Reduction in Eczema Area and Severity Index [EASI] at Week 52 Among Subjects With EASI75 at Week 16</title>
        <description>The EASI is a validated measure used in clinical practice and clinical trials to assess the severity and extent of AD. The EASI is a composite index with scores ranging from 0 to 72, with higher values indicating more severe and/or more extensive condition.</description>
        <time_frame>At Week 52</time_frame>
        <population>Maintenance analysis set: Subjects who achieved EASI75 at Week 16 after initial treatment with tralokinumab without use of rescue medication</population>
        <group_list>
          <group group_id="O1">
            <title>Tralokinumab 300 mg Q2W</title>
            <description>Week 16 to Week 52:&#xD;
Subjects achieving a clinical response at Week 16 and initially randomized to tralokinumab re-randomized to tralokinumab 300 mg Q2W maintenance dosing regimen&#xD;
At each visit, subject received 2 SC injections (each 1.0 mL) of 150 mg tralokinumab Q2W to receive a total dose of 300 mg tralokinumab.</description>
          </group>
          <group group_id="O2">
            <title>Tralokinumab 300 mg Q4W</title>
            <description>Week 16 to Week 52:&#xD;
Subjects achieving a clinical response at Week 16 and initially randomized to tralokinumab re-randomized to tralokinumab 300 mg Q4W maintenance dosing regimen&#xD;
At each visit, subject received alternating dose administrations: 2 SC injections (each 1.0 mL) of 150 mg tralokinumab to receive a total dose of 300 mg tralokinumab and 2 SC injections (each 1.0 mL) of placebo.</description>
          </group>
          <group group_id="O3">
            <title>Placebo Q2W</title>
            <description>Week 16 to Week 52:&#xD;
Subjects achieving a clinical response at Week 16 and initially randomized to tralokinumab re-randomized to placebo Q2W dosing regimen&#xD;
At each visit, subject received 2 SC injections (each 1.0 mL) of placebo Q2W to receive a total dose of placebo.</description>
          </group>
        </group_list>
        <measure>
          <title>Subjects With at Least 75% Reduction in Eczema Area and Severity Index [EASI] at Week 52 Among Subjects With EASI75 at Week 16</title>
          <description>The EASI is a validated measure used in clinical practice and clinical trials to assess the severity and extent of AD. The EASI is a composite index with scores ranging from 0 to 72, with higher values indicating more severe and/or more extensive condition.</description>
          <population>Maintenance analysis set: Subjects who achieved EASI75 at Week 16 after initial treatment with tralokinumab without use of rescue medication</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="77"/>
                <count group_id="O2" value="74"/>
                <count group_id="O3" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43"/>
                    <measurement group_id="O2" value="38"/>
                    <measurement group_id="O3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Testing according to the hierarchical testing procedure in the order:&#xD;
IGA 0/1 at Week 52 between Q2W vs Placebo, EASI75 at Week 52 between Q2W vs Placebo, IGA 0/1 at Week 52 between Q4W vs Placebo, and EASI75 at Week 52 between Q4W vs Placebo</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Based on the primary analysis of the primary estimand 'composite'. Subjects who received rescue medication or were transferred to open-label treatment are considered non-responders.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>33.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>17.3</ci_lower_limit>
            <ci_upper_limit>50.0</ci_upper_limit>
            <estimate_desc>Mantel-Haenszel risk difference compared to placebo, stratified by region.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Testing according to the hierarchical testing procedure in the order:&#xD;
IGA 0/1 at Week 52 between Q2W vs Placebo, EASI75 at Week 52 between Q2W vs Placebo, IGA 0/1 at Week 52 between Q4W vs Placebo, and EASI75 at Week 52 between Q4W vs Placebo</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.001</p_value>
            <p_value_desc>Test not evaluated for statistical significance. Based on the primary analysis of the 'composite' estimand. Subjects who received rescue medication or were transferred to open-label treatment were considered non-responders.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>30.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>13.7</ci_lower_limit>
            <ci_upper_limit>46.4</ci_upper_limit>
            <estimate_desc>Mantel-Haenszel risk difference compared to placebo, stratified by region.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety and Tolerability: Adverse Event (AE) /Serious Adverse Event (SAE) Frequency</title>
        <description>Overall summary of AEs and SAEs during the Initial treatment period is presented. For list of AEs and SAEs by MedDRA system organ class (SOC) and preferred term (PT) during the entire trial period (including safety follow-up), see Adverse Events Overview section.</description>
        <time_frame>Week 0 to Week 16</time_frame>
        <population>The analysis was performed on the safety analysis set. The safety analysis set comprised of participants who received at least 1 dose of IMP during the trial.</population>
        <group_list>
          <group group_id="O1">
            <title>Initial Treatment Period - Tralokinumab 300 mg Q2W</title>
            <description>Week 0 to Week 16:&#xD;
Tralokinumab 300 mg Q2W&#xD;
At Day 0, each subject received 4 SC injections (each 1.0 mL) of 150 mg tralokinumab to receive a total loading dose of 600 mg tralokinumab (4.0 mL). At subsequent visits (Q2W) each subject received 2 SC injections (each 1.0 mL) of 150 mg tralokinumab to receive a total dose of 300 mg tralokinumab</description>
          </group>
          <group group_id="O2">
            <title>Initial Treatment Period - Placebo Q2W</title>
            <description>Week 0 to Week 16:&#xD;
Placebo Q2W&#xD;
At Day 0, each subject received 4 SC injections (each 1.0 mL) of placebo to receive a total loading dose (4.0 mL). At subsequent visits (Q2W) each subject received 2 SC injections (each 1.0 mL) of placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Safety and Tolerability: Adverse Event (AE) /Serious Adverse Event (SAE) Frequency</title>
          <description>Overall summary of AEs and SAEs during the Initial treatment period is presented. For list of AEs and SAEs by MedDRA system organ class (SOC) and preferred term (PT) during the entire trial period (including safety follow-up), see Adverse Events Overview section.</description>
          <population>The analysis was performed on the safety analysis set. The safety analysis set comprised of participants who received at least 1 dose of IMP during the trial.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="592"/>
                <count group_id="O2" value="200"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="364"/>
                    <measurement group_id="O2" value="132"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Frequency of Anti-drug Antibodies</title>
        <description>Anti-tralokinumab antibody levels were analysed using a validated bioanalytical method</description>
        <time_frame>Week 0 to Week 16</time_frame>
        <population>All subjects in the safety analysis set are included</population>
        <group_list>
          <group group_id="O1">
            <title>Initial Treatment Period - Tralokinumab 300 mg Q2W</title>
            <description>Week 0 to Week 16:&#xD;
Tralokinumab 300 mg Q2W&#xD;
At Day 0, each subject received 4 SC injections (each 1.0 mL) of 150 mg tralokinumab to receive a total loading dose of 600 mg tralokinumab (4.0 mL). At subsequent visits (Q2W) each subject received 2 SC injections (each 1.0 mL) of 150 mg tralokinumab to receive a total dose of 300 mg tralokinumab</description>
          </group>
          <group group_id="O2">
            <title>Initial Treatment Period - Placebo Q2W</title>
            <description>Week 0 to Week 16:&#xD;
Placebo Q2W&#xD;
At Day 0, each subject received 4 SC injections (each 1.0 mL) of placebo to receive a total loading dose (4.0 mL). At subsequent visits (Q2W) each subject received 2 SC injections (each 1.0 mL) of placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Frequency of Anti-drug Antibodies</title>
          <description>Anti-tralokinumab antibody levels were analysed using a validated bioanalytical method</description>
          <population>All subjects in the safety analysis set are included</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="592"/>
                <count group_id="O2" value="200"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Total positive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pre existing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment emergent - Persistent</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Perishing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Negative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="558"/>
                    <measurement group_id="O2" value="185"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No post-baseline anti-drug antibody assessment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Subjects Achieving at Least 50% Reduction in Eczema Area and Severity Index [EASI] at Week 16</title>
        <description>The EASI is a validated measure used in clinical practice and clinical trials to assess the severity and extent of AD. The EASI is a composite index with scores ranging from 0 to 72, with higher values indicating more severe and/or more extensive condition.</description>
        <time_frame>At Week 16</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Tralokinumab 300 mg Q2W</title>
            <description>Week 0 to Week 16:&#xD;
Tralokinumab 300 mg Q2W&#xD;
At Day 0, each subject received 4 SC injections (each 1.0 mL) of 150 mg tralokinumab to receive a total loading dose of 600 mg tralokinumab (4.0 mL). At subsequent visits (Q2W) each subject received 2 SC injections (each 1.0 mL) of 150 mg tralokinumab to receive a total dose of 300 mg tralokinumab</description>
          </group>
          <group group_id="O2">
            <title>Placebo Q2W</title>
            <description>Week 0 to Week 16:&#xD;
Placebo Q2W&#xD;
At Day 0, each subject received 4 SC injections (each 1.0 mL) of placebo to receive a total loading dose (4.0 mL). At subsequent visits (Q2W) each subject received 2 SC injections (each 1.0 mL) of placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Subjects Achieving at Least 50% Reduction in Eczema Area and Severity Index [EASI] at Week 16</title>
          <description>The EASI is a validated measure used in clinical practice and clinical trials to assess the severity and extent of AD. The EASI is a composite index with scores ranging from 0 to 72, with higher values indicating more severe and/or more extensive condition.</description>
          <population>Full analysis set</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="591"/>
                <count group_id="O2" value="201"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="295"/>
                    <measurement group_id="O2" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Based on the primary analysis of the primary estimand 'composite'. Subjects with missing data or subjects who received rescue medication prior to Week 16 were considered non-responders.&#xD;
The statistical test was not controlled for multiplicity.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>29.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>22.5</ci_lower_limit>
            <ci_upper_limit>36.1</ci_upper_limit>
            <estimate_desc>Mantel-Haenszel risk difference, stratified by region and disease severity.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Subjects Achieving at Least 90% Reduction in Eczema Area and Severity Index [EASI] at Week 16.</title>
        <description>The EASI is a validated measure used in clinical practice and clinical trials to assess the severity and extent of AD. The EASI is a composite index with scores ranging from 0 to 72, with higher values indicating more severe and/or more extensive condition.</description>
        <time_frame>At Week 16</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Tralokinumab 300 mg Q2W</title>
            <description>Week 0 to Week 16:&#xD;
Tralokinumab 300 mg Q2W&#xD;
At Day 0, each subject received 4 SC injections (each 1.0 mL) of 150 mg tralokinumab to receive a total loading dose of 600 mg tralokinumab (4.0 mL). At subsequent visits (Q2W) each subject received 2 SC injections (each 1.0 mL) of 150 mg tralokinumab to receive a total dose of 300 mg tralokinumab</description>
          </group>
          <group group_id="O2">
            <title>Placebo Q2W</title>
            <description>Week 0 to Week 16:&#xD;
Placebo Q2W&#xD;
At Day 0, each subject received 4 SC injections (each 1.0 mL) of placebo to receive a total loading dose (4.0 mL). At subsequent visits (Q2W) each subject received 2 SC injections (each 1.0 mL) of placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Subjects Achieving at Least 90% Reduction in Eczema Area and Severity Index [EASI] at Week 16.</title>
          <description>The EASI is a validated measure used in clinical practice and clinical trials to assess the severity and extent of AD. The EASI is a composite index with scores ranging from 0 to 72, with higher values indicating more severe and/or more extensive condition.</description>
          <population>Full analysis set</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="591"/>
                <count group_id="O2" value="201"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="108"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Based on the primary analysis of the primary estimand 'composite'. Subjects with missing data or subjects who received rescue medication prior to Week 16 were considered non-responders.&#xD;
The statistical test was not controlled for multiplicity.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>12.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>8.3</ci_lower_limit>
            <ci_upper_limit>17.0</ci_upper_limit>
            <estimate_desc>Mantel-Haenszel risk difference, stratified by region and disease severity.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 16 in Eczema Area and Severity Index [EASI] Score</title>
        <description>The EASI is a validated measure used in clinical practice and clinical trials to assess the severity and extent of AD. The EASI is a composite index with scores ranging from 0 to 72, with higher values indicating more severe and/or more extensive condition.</description>
        <time_frame>At Week 16</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Tralokinumab 300 mg Q2W</title>
            <description>Week 0 to Week 16:&#xD;
Tralokinumab 300 mg Q2W&#xD;
At Day 0, each subject received 4 SC injections (each 1.0 mL) of 150 mg tralokinumab to receive a total loading dose of 600 mg tralokinumab (4.0 mL). At subsequent visits (Q2W) each subject received 2 SC injections (each 1.0 mL) of 150 mg tralokinumab to receive a total dose of 300 mg tralokinumab</description>
          </group>
          <group group_id="O2">
            <title>Placebo Q2W</title>
            <description>Week 0 to Week 16:&#xD;
Placebo Q2W&#xD;
At Day 0, each subject received 4 SC injections (each 1.0 mL) of placebo to receive a total loading dose (4.0 mL). At subsequent visits (Q2W) each subject received 2 SC injections (each 1.0 mL) of placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 16 in Eczema Area and Severity Index [EASI] Score</title>
          <description>The EASI is a validated measure used in clinical practice and clinical trials to assess the severity and extent of AD. The EASI is a composite index with scores ranging from 0 to 72, with higher values indicating more severe and/or more extensive condition.</description>
          <population>Full analysis set</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="591"/>
                <count group_id="O2" value="201"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-16.9" lower_limit="-18.0" upper_limit="-15.8"/>
                    <measurement group_id="O2" value="-7.0" lower_limit="-9.1" upper_limit="-5.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Data collected after permanent discontinuation of IMP or initiation of rescue medication not included. In case of no post-baseline assessments before initiation of rescue medication, the Week 2 change will be imputed as 0.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The statistical test was not controlled for multiplicity.</p_value_desc>
            <method>Repeated measurements model</method>
            <param_type>Difference of least square means</param_type>
            <param_value>-9.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-12.2</ci_lower_limit>
            <ci_upper_limit>-7.5</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Subjects Achieving at Least 75% Reduction in Scoring Atopic Dermatitis (SCORAD) at Week 16.</title>
        <description>The SCORAD is a validated tool to evaluate the extent and severity of AD lesions, along with subjective symptoms. The maximum total score is 103, with higher values indicating more severe disease.</description>
        <time_frame>At Week 16</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Tralokinumab 300 mg Q2W</title>
            <description>Week 0 to Week 16:&#xD;
Tralokinumab 300 mg Q2W&#xD;
At Day 0, each subject received 4 SC injections (each 1.0 mL) of 150 mg tralokinumab to receive a total loading dose of 600 mg tralokinumab (4.0 mL). At subsequent visits (Q2W) each subject received 2 SC injections (each 1.0 mL) of 150 mg tralokinumab to receive a total dose of 300 mg tralokinumab</description>
          </group>
          <group group_id="O2">
            <title>Placebo Q2W</title>
            <description>Week 0 to Week 16:&#xD;
Placebo Q2W&#xD;
At Day 0, each subject received 4 SC injections (each 1.0 mL) of placebo to receive a total loading dose (4.0 mL). At subsequent visits (Q2W) each subject received 2 SC injections (each 1.0 mL) of placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Subjects Achieving at Least 75% Reduction in Scoring Atopic Dermatitis (SCORAD) at Week 16.</title>
          <description>The SCORAD is a validated tool to evaluate the extent and severity of AD lesions, along with subjective symptoms. The maximum total score is 103, with higher values indicating more severe disease.</description>
          <population>Full analysis set</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="591"/>
                <count group_id="O2" value="201"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Based on the primary analysis of the 'composite' estimand. Subjects who received rescue medication prior to Week 16 or with missing data at Week 16 were considered non-responders.&#xD;
The statistical test was not controlled for multiplicity.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>8.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>4.4</ci_lower_limit>
            <ci_upper_limit>11.6</ci_upper_limit>
            <estimate_desc>Mantel-Haenszel risk difference, stratified by region and baseline disease severity.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Subjects Achieving at Least 50% Reduction in Scoring Atopic Dermatitis (SCORAD) at Week 16.</title>
        <description>The SCORAD is a validated tool to evaluate the extent and severity of AD lesions, along with subjective symptoms. The maximum total score is 103, with higher values indicating more severe disease.</description>
        <time_frame>At Week 16</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Tralokinumab 300 mg Q2W</title>
            <description>Week 0 to Week 16:&#xD;
Tralokinumab 300 mg Q2W&#xD;
At Day 0, each subject received 4 SC injections (each 1.0 mL) of 150 mg tralokinumab to receive a total loading dose of 600 mg tralokinumab (4.0 mL). At subsequent visits (Q2W) each subject received 2 SC injections (each 1.0 mL) of 150 mg tralokinumab to receive a total dose of 300 mg tralokinumab</description>
          </group>
          <group group_id="O2">
            <title>Placebo Q2W</title>
            <description>Week 0 to Week 16:&#xD;
Placebo Q2W&#xD;
At Day 0, each subject received 4 SC injections (each 1.0 mL) of placebo to receive a total loading dose (4.0 mL). At subsequent visits (Q2W) each subject received 2 SC injections (each 1.0 mL) of placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Subjects Achieving at Least 50% Reduction in Scoring Atopic Dermatitis (SCORAD) at Week 16.</title>
          <description>The SCORAD is a validated tool to evaluate the extent and severity of AD lesions, along with subjective symptoms. The maximum total score is 103, with higher values indicating more severe disease.</description>
          <population>Full analysis set</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="591"/>
                <count group_id="O2" value="201"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="198"/>
                    <measurement group_id="O2" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Based on the primary analysis of the 'composite' estimand. Subjects who received rescue medication prior to Week 16 or with missing data at Week 16 were considered non-responders.&#xD;
The statistical test was not controlled for multiplicity.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>18.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>12.8</ci_lower_limit>
            <ci_upper_limit>25.1</ci_upper_limit>
            <estimate_desc>Mantel-Haenszel risk difference stratified by region and disease severity.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 16 in Worst Daily Pruritus NRS (Weekly Average).</title>
        <description>Subjects will assess their worst itch severity over the past 24 hours using an 11 point NRS ('Worst Daily Pruritus NRS') with 0 indicating 'no itch' and 10 indicating 'worst itch imaginable'</description>
        <time_frame>Baseline to Week 16</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Tralokinumab 300 mg Q2W</title>
            <description>Week 0 to Week 16:&#xD;
Tralokinumab 300 mg Q2W&#xD;
At Day 0, each subject received 4 SC injections (each 1.0 mL) of 150 mg tralokinumab to receive a total loading dose of 600 mg tralokinumab (4.0 mL). At subsequent visits (Q2W) each subject received 2 SC injections (each 1.0 mL) of 150 mg tralokinumab to receive a total dose of 300 mg tralokinumab</description>
          </group>
          <group group_id="O2">
            <title>Placebo Q2W</title>
            <description>Week 0 to Week 16:&#xD;
Placebo Q2W&#xD;
At Day 0, each subject received 4 SC injections (each 1.0 mL) of placebo to receive a total loading dose (4.0 mL). At subsequent visits (Q2W) each subject received 2 SC injections (each 1.0 mL) of placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 16 in Worst Daily Pruritus NRS (Weekly Average).</title>
          <description>Subjects will assess their worst itch severity over the past 24 hours using an 11 point NRS ('Worst Daily Pruritus NRS') with 0 indicating 'no itch' and 10 indicating 'worst itch imaginable'</description>
          <population>Full analysis set</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="584"/>
                <count group_id="O2" value="200"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.9" lower_limit="-3.1" upper_limit="-2.6"/>
                    <measurement group_id="O2" value="-1.6" lower_limit="-2.0" upper_limit="-1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Data collected after permanent discontinuation of IMP or initiation of rescue medication not included. In case of no post-baseline assessments before initiation of rescue medication, the Week 1 change will be imputed as 0.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The statistical test was not controlled for multiplicity.</p_value_desc>
            <method>Repeated measurements model</method>
            <param_type>Difference of least square means</param_type>
            <param_value>-1.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.7</ci_lower_limit>
            <ci_upper_limit>-0.8</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Reduction of Worst Daily Pruritus NRS (Weekly Average) ≥3 From Baseline to Week 16.</title>
        <description>Subjects will assess their worst itch severity over the past 24 hours using an 11 point NRS ('Worst Daily Pruritus NRS') with 0 indicating 'no itch' and 10 indicating 'worst itch imaginable'.</description>
        <time_frame>Baseline to Week 16</time_frame>
        <population>Full analysis set. Number of subjects analysed = subjects with baseline Pruritus NRS weekly average of at least 3</population>
        <group_list>
          <group group_id="O1">
            <title>Tralokinumab 300 mg Q2W</title>
            <description>Week 0 to Week 16:&#xD;
Tralokinumab 300 mg Q2W&#xD;
At Day 0, each subject received 4 SC injections (each 1.0 mL) of 150 mg tralokinumab to receive a total loading dose of 600 mg tralokinumab (4.0 mL). At subsequent visits (Q2W) each subject received 2 SC injections (each 1.0 mL) of 150 mg tralokinumab to receive a total dose of 300 mg tralokinumab</description>
          </group>
          <group group_id="O2">
            <title>Placebo Q2W</title>
            <description>Week 0 to Week 16:&#xD;
Placebo Q2W&#xD;
At Day 0, each subject received 4 SC injections (each 1.0 mL) of placebo to receive a total loading dose (4.0 mL). At subsequent visits (Q2W) each subject received 2 SC injections (each 1.0 mL) of placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Reduction of Worst Daily Pruritus NRS (Weekly Average) ≥3 From Baseline to Week 16.</title>
          <description>Subjects will assess their worst itch severity over the past 24 hours using an 11 point NRS ('Worst Daily Pruritus NRS') with 0 indicating 'no itch' and 10 indicating 'worst itch imaginable'.</description>
          <population>Full analysis set. Number of subjects analysed = subjects with baseline Pruritus NRS weekly average of at least 3</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="583"/>
                <count group_id="O2" value="200"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="199"/>
                    <measurement group_id="O2" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Subjects who received rescue medication prior to Week 16 or have missing data at Week 16 were considered as non-responders.&#xD;
The statistical test was not controlled for multiplicity.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>20.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>13.9</ci_lower_limit>
            <ci_upper_limit>26.2</ci_upper_limit>
            <estimate_desc>Mantel-Haenszel risk difference, stratified by region and baseline disease severity.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Reduction From Baseline to Week 16 of Dermatology Life Quality Index (DLQI) of ≥4 Points Among Subjects With Baseline DLQI ≥4.</title>
        <description>The DLQI is a validated questionnaire with content specific to those with dermatology conditions. It consists of 10 items addressing the subject's perception of the impact of their skin disease on different aspects of their QoL over the last week such as dermatology related symptoms and feelings, daily activities, leisure, work or school, personal relationships, and the treatment. Each item is scored on a 4 point Likert scale (0 = not at all/not relevant; 1 = a little; 2 = a lot; 3 = very much). The total score is the sum of the 10 items (0 to 30); a high score is indicative of a poor QoL.</description>
        <time_frame>Baseline to Week 16</time_frame>
        <population>Full analysis set. Number of subjects analysed = subjects with baseline DLQI ≥4</population>
        <group_list>
          <group group_id="O1">
            <title>Tralokinumab 300 mg Q2W</title>
            <description>Week 0 to Week 16:&#xD;
Tralokinumab 300 mg Q2W&#xD;
At Day 0, each subject received 4 SC injections (each 1.0 mL) of 150 mg tralokinumab to receive a total loading dose of 600 mg tralokinumab (4.0 mL). At subsequent visits (Q2W) each subject received 2 SC injections (each 1.0 mL) of 150 mg tralokinumab to receive a total dose of 300 mg tralokinumab</description>
          </group>
          <group group_id="O2">
            <title>Placebo Q2W</title>
            <description>Week 0 to Week 16:&#xD;
Placebo Q2W&#xD;
At Day 0, each subject received 4 SC injections (each 1.0 mL) of placebo to receive a total loading dose (4.0 mL). At subsequent visits (Q2W) each subject received 2 SC injections (each 1.0 mL) of placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Reduction From Baseline to Week 16 of Dermatology Life Quality Index (DLQI) of ≥4 Points Among Subjects With Baseline DLQI ≥4.</title>
          <description>The DLQI is a validated questionnaire with content specific to those with dermatology conditions. It consists of 10 items addressing the subject's perception of the impact of their skin disease on different aspects of their QoL over the last week such as dermatology related symptoms and feelings, daily activities, leisure, work or school, personal relationships, and the treatment. Each item is scored on a 4 point Likert scale (0 = not at all/not relevant; 1 = a little; 2 = a lot; 3 = very much). The total score is the sum of the 10 items (0 to 30); a high score is indicative of a poor QoL.</description>
          <population>Full analysis set. Number of subjects analysed = subjects with baseline DLQI ≥4</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="577"/>
                <count group_id="O2" value="198"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="325"/>
                    <measurement group_id="O2" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Subjects who received rescue medication prior to Week 16 or have missing data at Week 16 were considered as non-responders.&#xD;
The statistical test was not controlled for multiplicity.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>28.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>21.4</ci_lower_limit>
            <ci_upper_limit>36.3</ci_upper_limit>
            <estimate_desc>Mantel-Haenszel risk difference, stratified by region and baseline disease severity.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Initial Treatment Period: Week 0 to Week 16; Maintenance Treatment Period: Week 16 to Week 52; Open-label Treatment: Week 16 to Week 52; Safety follow-up Period (All treatment arms): Week 52 to Week 66</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Initial Period - Tralokinumab Q2W</title>
          <description>Initial Period - Tralokinumab Q2W (n=592, patient years of exposure (PYE)=176.90)</description>
        </group>
        <group group_id="E2">
          <title>Initial Period - Placebo</title>
          <description>Initial Period - Placebo (n=200, PYE=57.35)</description>
        </group>
        <group group_id="E3">
          <title>Maintenance Period - Tralokinumab Q2W</title>
          <description>Maintenance Period - Tralokinumab Q2W (n=91, PYE=46.93)</description>
        </group>
        <group group_id="E4">
          <title>Maintenance Period - Tralokinumab Q4W</title>
          <description>Maintenance Period - Tralokinumab Q4W (n=89, PYE=44.65)</description>
        </group>
        <group group_id="E5">
          <title>Maintenance Period - Placebo</title>
          <description>Maintenance Period - Placebo (n=46, PYE=20.07)</description>
        </group>
        <group group_id="E6">
          <title>Maintenance Period - Placebo - Tralokinumab Naive</title>
          <description>Maintenance Period - Placebo - Tralokinumab Naive (n=31, PYE=15.09)</description>
        </group>
        <group group_id="E7">
          <title>Open-label Period - Tralokinumab Q2W + Optional TCS</title>
          <description>Open-label Period - Tralokinumab Q2W + Optional TCS (n=558, PYE=315.48)</description>
        </group>
        <group group_id="E8">
          <title>Safety Follow-up</title>
          <description>Safety Follow-up (n=641, PYE=142.90) includes subjects from Initial, Maintenance and Open-label Periods:&#xD;
Tralokinumab Q2W (n=83); Tralokinumab Q4W (n=50); Tralokinumab Q2W + optional TCS (n=454); Placebo (n=54)</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 20.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="592"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="641"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="592"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="200"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="89"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E7" subjects_affected="16" subjects_at_risk="558"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="641"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Benign ethnic neutropenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="592"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="558"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="641"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Pericarditis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="592"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="200"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="641"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract subcapsular</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="592"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="200"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="641"/>
              </event>
              <event>
                <sub_title>Retinal detachment</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="592"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="558"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="641"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="592"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="200"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="641"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="592"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="641"/>
              </event>
              <event>
                <sub_title>Gastric perforation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="592"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="641"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaphylactic reaction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="592"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="558"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="641"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Eczema herpeticum</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="592"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="641"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="592"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="641"/>
              </event>
              <event>
                <sub_title>Keratitis viral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="592"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="558"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="641"/>
              </event>
              <event>
                <sub_title>Pilonidal cyst</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="592"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="200"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="641"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="592"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="558"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="641"/>
              </event>
              <event>
                <sub_title>Skin infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="592"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="200"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="641"/>
              </event>
              <event>
                <sub_title>Staphylococcal abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="592"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="641"/>
              </event>
              <event>
                <sub_title>Staphylococcal bacteraemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="592"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="558"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="641"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Facial bones fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="592"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="558"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="641"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="592"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="558"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="641"/>
              </event>
              <event>
                <sub_title>Intentional overdose</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="592"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="641"/>
              </event>
              <event>
                <sub_title>Radius fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="592"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="558"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="641"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="592"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="558"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="641"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Angiosarcoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="592"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="641"/>
              </event>
              <event>
                <sub_title>Papillary thyroid cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="592"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="641"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of skin</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="592"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="641"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="592"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="641"/>
              </event>
              <event>
                <sub_title>Neurological symptom</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="592"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="558"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="641"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="592"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="558"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="641"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Product Issues</title>
            <event_list>
              <event>
                <sub_title>Device dislocation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="592"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="558"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="641"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression suicidal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="592"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="641"/>
              </event>
              <event>
                <sub_title>Schizophrenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="592"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="641"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="592"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="558"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="641"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="592"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="641"/>
              </event>
              <event>
                <sub_title>Status asthmaticus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="592"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="641"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis atopic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="592"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="558"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="641"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="592"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="200"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="641"/>
              </event>
              <event>
                <sub_title>Photosensitivity reaction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="592"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="558"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="641"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Ovarian cystectomy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="592"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="558"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="641"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 20.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="202" subjects_at_risk="592"/>
                <counts group_id="E2" subjects_affected="89" subjects_at_risk="200"/>
                <counts group_id="E3" subjects_affected="37" subjects_at_risk="91"/>
                <counts group_id="E4" subjects_affected="28" subjects_at_risk="89"/>
                <counts group_id="E5" subjects_affected="21" subjects_at_risk="46"/>
                <counts group_id="E6" subjects_affected="9" subjects_at_risk="31"/>
                <counts group_id="E7" subjects_affected="226" subjects_at_risk="558"/>
                <counts group_id="E8" subjects_affected="28" subjects_at_risk="641"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Dry eye</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="592"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="200"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="91"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E5" events="4" subjects_affected="3" subjects_at_risk="46"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E7" events="5" subjects_affected="5" subjects_at_risk="558"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="641"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" events="21" subjects_affected="18" subjects_at_risk="592"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="200"/>
                <counts group_id="E3" events="8" subjects_affected="5" subjects_at_risk="91"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="46"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E7" events="23" subjects_affected="22" subjects_at_risk="558"/>
                <counts group_id="E8" events="3" subjects_affected="3" subjects_at_risk="641"/>
              </event>
              <event>
                <sub_title>Oral herpes</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="592"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="200"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="91"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E7" events="7" subjects_affected="7" subjects_at_risk="558"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="641"/>
              </event>
              <event>
                <sub_title>Skin infection</sub_title>
                <counts group_id="E1" events="13" subjects_affected="12" subjects_at_risk="592"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="200"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="91"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E7" events="13" subjects_affected="11" subjects_at_risk="558"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="641"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="65" subjects_affected="59" subjects_at_risk="592"/>
                <counts group_id="E2" events="17" subjects_affected="17" subjects_at_risk="200"/>
                <counts group_id="E3" events="18" subjects_affected="14" subjects_at_risk="91"/>
                <counts group_id="E4" events="12" subjects_affected="9" subjects_at_risk="89"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="46"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E7" events="87" subjects_affected="65" subjects_at_risk="558"/>
                <counts group_id="E8" events="7" subjects_affected="6" subjects_at_risk="641"/>
              </event>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="52" subjects_affected="49" subjects_at_risk="592"/>
                <counts group_id="E2" events="19" subjects_affected="17" subjects_at_risk="200"/>
                <counts group_id="E3" events="10" subjects_affected="9" subjects_at_risk="91"/>
                <counts group_id="E4" events="6" subjects_affected="6" subjects_at_risk="89"/>
                <counts group_id="E5" events="7" subjects_affected="7" subjects_at_risk="46"/>
                <counts group_id="E6" events="7" subjects_affected="4" subjects_at_risk="31"/>
                <counts group_id="E7" events="83" subjects_affected="58" subjects_at_risk="558"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="641"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" events="13" subjects_affected="6" subjects_at_risk="592"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="200"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="91"/>
                <counts group_id="E4" events="4" subjects_affected="3" subjects_at_risk="89"/>
                <counts group_id="E5" events="4" subjects_affected="3" subjects_at_risk="46"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E7" events="8" subjects_affected="8" subjects_at_risk="558"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="641"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis atopic</sub_title>
                <counts group_id="E1" events="131" subjects_affected="97" subjects_at_risk="592"/>
                <counts group_id="E2" events="97" subjects_affected="67" subjects_at_risk="200"/>
                <counts group_id="E3" events="25" subjects_affected="13" subjects_at_risk="91"/>
                <counts group_id="E4" events="19" subjects_affected="14" subjects_at_risk="89"/>
                <counts group_id="E5" events="16" subjects_affected="9" subjects_at_risk="46"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E7" events="174" subjects_affected="114" subjects_at_risk="558"/>
                <counts group_id="E8" events="15" subjects_affected="15" subjects_at_risk="641"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="592"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="200"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="91"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="46"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E7" events="6" subjects_affected="6" subjects_at_risk="558"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="641"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>LEO Pharma seeks publication of all Phase 3 clinical trials in peer-reviewed journals within 18 months of trial completion, regardless of whether the findings are positive or negative. If there is no multi-centre publication within 18 months after the clinical trial has been completed or terminated at all trial sites, the investigator has the right to publish the results from the clinical trial generated by the investigator.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Disclosure</name_or_title>
      <organization>LEO Pharma A/S</organization>
      <phone>+45 44945888</phone>
      <email>disclosure@leo-pharma.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

